ProfileGDS5678 / 1454254_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 20% 21% 22% 22% 36% 20% 21% 51% 42% 22% 21% 22% 21% 20% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5122920
GSM967853U87-EV human glioblastoma xenograft - Control 22.4855821
GSM967854U87-EV human glioblastoma xenograft - Control 32.5093222
GSM967855U87-EV human glioblastoma xenograft - Control 42.4625422
GSM967856U87-EV human glioblastoma xenograft - Control 52.7636536
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5408520
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5256121
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2278151
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9431242
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4981422
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.493721
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4817622
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5044921
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4760620